Overview

Effect of Ursodeoxycholic Acid on Peritoneal Function in Patients on Peritoneal Dialysis

Status:
Unknown status

Trial end date:
2018-01-01

Target enrollment:
0

Participant gender:
All

Summary

Peritoneal fibrosis is one of the major causes of technical failure in patients on peritoneal dialysis (PD) for long period of time. Although the exact mechanisms of peritoneal damage during PD still remain unclear, generation of Endoplasmic reticulum (ER) stress may be responsible for progressive membrane dysfunction. Ursodeoxycholic acid (URSA) is a powerful inhibitor of ER stress to protect peritoneal fibrosis in peritoneal dialysis in the investigators in-vitro study. In this study the researchers investigated the hypothesis that URSA protect peritoneal membrane damage.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Ewha Womans University

Treatments:

Ursodeoxycholic Acid

Criteria

Inclusion Criteria:

- Maintenance peritoneal dialysis at least 3 months

- Patients who are able and willing to understand, sign and date an informed consent
document, and authorize access to protected health information

Exclusion Criteria:

- Episode of peritonitis at least 3 months

- Episodes of admission due to other disease at lease 3 months

- Liver disease

- Allergic history with Ursodeoxycholic acid

- Nausea or vomiting after Ursodeoxycholic acid